Presented in part at the Annual Meeting of the Taiwan Society of Nephrology held 8–9 December 2007, in Taipei, Taiwan.
Impact of Renal Survival on the Course and Outcome of Systemic Lupus Erythematosus Patients Treated With Chronic Peritoneal Dialysis
Article first published online: 17 JUL 2009
© 2009 The Authors. Journal compilation © 2009 International Society for Apheresis
Therapeutic Apheresis and Dialysis
Volume 14, Issue 1, pages 35–42, February 2010
How to Cite
Liang, C.-C., Huang, C.-C., Wang, I.-K., Chang, C.-T., Chen, K.-H., Weng, C.-H., Lin, J.-L., Hung, C.-C., Yang, C.-W. and Yen, T.-H. (2010), Impact of Renal Survival on the Course and Outcome of Systemic Lupus Erythematosus Patients Treated With Chronic Peritoneal Dialysis. Therapeutic Apheresis and Dialysis, 14: 35–42. doi: 10.1111/j.1744-9987.2009.00703.x
- Issue published online: 12 FEB 2010
- Article first published online: 17 JUL 2009
- Received December 2008; revised March 2009.
- Peritoneal dialysis;
- Peritoneal solute transporter rate;
- Renal survival;
- Systemic lupus erythematosus
This longitudinal study investigated whether renal survival can affect the course and outcome of systemic lupus erythematosus (SLE) patients treated with chronic peritoneal dialysis (PD). Thirty-five SLE patients, out of 1115 end-stage renal disease (ESRD) patients treated with chronic PD, were seen between 1990 and 2007 at the Chang Gung Memorial Hospital. Patients were followed up for a mean of 38.8 ± 22.9 months. There were no significant differences between patients with short renal survival (<3 years) and long renal survival (>3 years) for the various demographic variables such as age, sex, PD duration, immunosuppressive drug administration, or exchange system (P > 0.05). Interestingly, before PD, patients with short renal survival had lower serum complement levels than patients with long renal survival (C3, 40.2 ± 14.4 vs 76.3 ± 18.5 mg/dL, P < 0.001; and C4, 14.8 ± 4.7 vs 22.4 ± 8.1 mg/dL, P < 0.05). However, the differences in complement levels between the groups disappeared after PD (C3, 76.5 ± 27.3 vs 84.2 ± 27.8 mg/dL; and C4, 26.7 ± 11.3 vs 22.6 ± 10.8 mg/dL, both P > 0.05). Patients with short renal survival were more likely to have a high peritoneal solute transporter rate (PSTR) than their long renal survival counterparts (χ2-test, P = 0.02, and AUROC = 0.744 and P = 0.040); however, there were no significant differences for other variables such as cardiothoracic ratio (CTR), Kt/V, residual renal function, exit site infection, and peritonitis (P > 0.05). Finally, Kaplan–Meier analysis revealed that the two groups did not differ in patient and technical survival (P > 0.05). Therefore it was concluded that renal survival might be associated with PSTR, but not with patient and technical survival in SLE patients treated with PD.